National Taiwan University Hospital – Developmental Therapeutics Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “National Taiwan University Hospital – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “National Taiwan University Hospital – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
- Review of therapeutics under development by National Taiwan University Hospital.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of National Taiwan University Hospital with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of National Taiwan University Hospital’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Identify new drug targets and therapeutic classes in National Taiwan University Hospital’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate National Taiwan University Hospital’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of National Taiwan University Hospital in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with National Taiwan University Hospital.
- Avoid Intellectual Property Rights related issues.
National Taiwan University Hospital Snapshot
National Taiwan University Hospital Overview
Key Information
Key Facts
National Taiwan University Hospital – Research and Development Overview
Key Therapeutic Areas
National Taiwan University Hospital – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
National Taiwan University Hospital – Pipeline Products Glance
National Taiwan University Hospital – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
National Taiwan University Hospital Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
National Taiwan University Hospital – Drug Profiles
Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Bevacizumab_
Product Description
Mechanism of Action
R&D Progress
intrapleural minocycline instillation
Product Description
Mechanism of Action
R&D Progress
Isoniazid
Product Description
Mechanism of Action
R&D Progress
Minocycline
Product Description
Mechanism of Action
R&D Progress
Olanzapine
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline
Product Description
Mechanism of Action
R&D Progress
Proton pump inhibitor
Product Description
Mechanism of Action
R&D Progress
Rifampin
Product Description
Mechanism of Action
R&D Progress
Taxotere + Epirubine
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Cisplatin + 5-Fluorouracil + Leucovorin
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Paclitaxel + Cisplatin + Radiotherapy
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Paclitaxel + Cisplatin|Radiation: Radiotherapy
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Cisplatin + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Irinotecan
Product Description
Mechanism of Action
R&D Progress
Docetaxel/Irinotecan
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Epirubicin
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Ifosfamide
Product Description
Mechanism of Action
R&D Progress
Iressa
Product Description
Mechanism of Action
R&D Progress
Lapatinib + Vinorelbine_
Product Description
Mechanism of Action
R&D Progress
Lycopene
Product Description
Mechanism of Action
R&D Progress
Mycostatin
Product Description
Mechanism of Action
R&D Progress
N-acetyl cysteine
Product Description
Mechanism of Action
R&D Progress
oxaliplatin + gemcitabine + 5-FU/LV
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + 5-Fluorouracil + Leucovorin
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + 5-Fluorouracil
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + 5-Fluorouracil + Folinic acid
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + Radiation for Esophageal Cancer (National Taiwan University Hospital)
Product Description
Mechanism of Action
R&D Progress
Paclitaxel-HDFL
Product Description
Mechanism of Action
R&D Progress
PDC-339
Product Description
Mechanism of Action
R&D Progress
RAD001 + Cisplatin + 5-Fluorouracil + Leucovorin
Product Description
Mechanism of Action
R&D Progress
RAD001 + Cisplatin + 5-FU + Leucovorin
Product Description
Mechanism of Action
R&D Progress
Sitagliptin
Product Description
Mechanism of Action
R&D Progress
Sorafenib + tegafur/uracil
Product Description
Mechanism of Action
R&D Progress
Taxol + UFT + Leucovorin
Product Description
Mechanism of Action
R&D Progress
Taxteral + 5-Fluorouracil + Leucovorin
Product Description
Mechanism of Action
R&D Progress
tegafur + uraci + thalidomide
Product Description
Mechanism of Action
R&D Progress
Thalidomide + Radiation theraphy
Product Description
Mechanism of Action
R&D Progress
Thalidomide + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
MK-2206
Product Description
Mechanism of Action
R&D Progress
Tisseel
Product Description
Mechanism of Action
R&D Progress
National Taiwan University Hospital – Pipeline Analysis
National Taiwan University Hospital – Pipeline Products by Therapeutic Class
National Taiwan University Hospital Pipeline Products By Target
National Taiwan University Hospital – Pipeline Products by Route of Administration
National Taiwan University Hospital – Pipeline Products by Molecule Type
National Taiwan University Hospital - Dormant Projects
National Taiwan University Hospital – Locations And Subsidiaries
Head Office
Financial Deals Landscape
National Taiwan University Hospital, Deals Summary, 2004 to 2010
National Taiwan University Hospital Detailed Deal Summary
Exactech Signs An Agreement With Industrial Technology Research Institute And National Taiwan University Hospital
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
National Taiwan University Hospital – Pipeline by Therapy Area and Indication, 2010
National Taiwan University Hospital – Pipeline by Stage of Development, 2010
National Taiwan University Hospital – Monotherapy Products in Pipeline, 2010
National Taiwan University Hospital – Combination Treatment Modalities in Pipeline, 2010
National Taiwan University Hospital – Phase III, 2010
National Taiwan University Hospital - Phase II, 2010
National Taiwan University Hospital - Phase I, 2010
National Taiwan University Hospital - Pipeline By Therapeutic Class, 2010
National Taiwan University Hospital - Pipeline By Target, 2010
National Taiwan University Hospital – Pipeline By Route of Administration, 2010
National Taiwan University Hospital – Pipeline By Molecule Type, 2010
National Taiwan University Hospital - Dormant Developmental Projects, 2010
National Taiwan University Hospital, Deals Summary, 2004 to 2010 87
LIST OF FIGURES
National Taiwan University Hospital – Pipeline by Therapy Area and Indication, 2010
National Taiwan University Hospital – Pipeline by Stage of Development, 2010
National Taiwan University Hospital – Monotherapy Products in Pipeline, 2010
National Taiwan University Hospital – Combination Treatment Modalities in Pipeline, 2010
National Taiwan University Hospital – Pipeline By Therapeutic Class, 2010
National Taiwan University Hospital - Pipeline By Target, 2010
National Taiwan University Hospital – Pipeline By Route of Administration, 2010
National Taiwan University Hospital – Pipeline By Molecule Type, 2010 85
National Taiwan University Hospital Overview
Key Information
Key Facts
National Taiwan University Hospital – Research and Development Overview
Key Therapeutic Areas
National Taiwan University Hospital – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
National Taiwan University Hospital – Pipeline Products Glance
National Taiwan University Hospital – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
National Taiwan University Hospital Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
National Taiwan University Hospital – Drug Profiles
Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Bevacizumab_
Product Description
Mechanism of Action
R&D Progress
intrapleural minocycline instillation
Product Description
Mechanism of Action
R&D Progress
Isoniazid
Product Description
Mechanism of Action
R&D Progress
Minocycline
Product Description
Mechanism of Action
R&D Progress
Olanzapine
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline
Product Description
Mechanism of Action
R&D Progress
Proton pump inhibitor
Product Description
Mechanism of Action
R&D Progress
Rifampin
Product Description
Mechanism of Action
R&D Progress
Taxotere + Epirubine
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Cisplatin + 5-Fluorouracil + Leucovorin
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Paclitaxel + Cisplatin + Radiotherapy
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Paclitaxel + Cisplatin|Radiation: Radiotherapy
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Cisplatin + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Irinotecan
Product Description
Mechanism of Action
R&D Progress
Docetaxel/Irinotecan
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Epirubicin
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Ifosfamide
Product Description
Mechanism of Action
R&D Progress
Iressa
Product Description
Mechanism of Action
R&D Progress
Lapatinib + Vinorelbine_
Product Description
Mechanism of Action
R&D Progress
Lycopene
Product Description
Mechanism of Action
R&D Progress
Mycostatin
Product Description
Mechanism of Action
R&D Progress
N-acetyl cysteine
Product Description
Mechanism of Action
R&D Progress
oxaliplatin + gemcitabine + 5-FU/LV
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + 5-Fluorouracil + Leucovorin
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + 5-Fluorouracil
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + 5-Fluorouracil + Folinic acid
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + Radiation for Esophageal Cancer (National Taiwan University Hospital)
Product Description
Mechanism of Action
R&D Progress
Paclitaxel-HDFL
Product Description
Mechanism of Action
R&D Progress
PDC-339
Product Description
Mechanism of Action
R&D Progress
RAD001 + Cisplatin + 5-Fluorouracil + Leucovorin
Product Description
Mechanism of Action
R&D Progress
RAD001 + Cisplatin + 5-FU + Leucovorin
Product Description
Mechanism of Action
R&D Progress
Sitagliptin
Product Description
Mechanism of Action
R&D Progress
Sorafenib + tegafur/uracil
Product Description
Mechanism of Action
R&D Progress
Taxol + UFT + Leucovorin
Product Description
Mechanism of Action
R&D Progress
Taxteral + 5-Fluorouracil + Leucovorin
Product Description
Mechanism of Action
R&D Progress
tegafur + uraci + thalidomide
Product Description
Mechanism of Action
R&D Progress
Thalidomide + Radiation theraphy
Product Description
Mechanism of Action
R&D Progress
Thalidomide + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
MK-2206
Product Description
Mechanism of Action
R&D Progress
Tisseel
Product Description
Mechanism of Action
R&D Progress
National Taiwan University Hospital – Pipeline Analysis
National Taiwan University Hospital – Pipeline Products by Therapeutic Class
National Taiwan University Hospital Pipeline Products By Target
National Taiwan University Hospital – Pipeline Products by Route of Administration
National Taiwan University Hospital – Pipeline Products by Molecule Type
National Taiwan University Hospital - Dormant Projects
National Taiwan University Hospital – Locations And Subsidiaries
Head Office
Financial Deals Landscape
National Taiwan University Hospital, Deals Summary, 2004 to 2010
National Taiwan University Hospital Detailed Deal Summary
Exactech Signs An Agreement With Industrial Technology Research Institute And National Taiwan University Hospital
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
National Taiwan University Hospital – Pipeline by Therapy Area and Indication, 2010
National Taiwan University Hospital – Pipeline by Stage of Development, 2010
National Taiwan University Hospital – Monotherapy Products in Pipeline, 2010
National Taiwan University Hospital – Combination Treatment Modalities in Pipeline, 2010
National Taiwan University Hospital – Phase III, 2010
National Taiwan University Hospital - Phase II, 2010
National Taiwan University Hospital - Phase I, 2010
National Taiwan University Hospital - Pipeline By Therapeutic Class, 2010
National Taiwan University Hospital - Pipeline By Target, 2010
National Taiwan University Hospital – Pipeline By Route of Administration, 2010
National Taiwan University Hospital – Pipeline By Molecule Type, 2010
National Taiwan University Hospital - Dormant Developmental Projects, 2010
National Taiwan University Hospital, Deals Summary, 2004 to 2010 87
LIST OF FIGURES
National Taiwan University Hospital – Pipeline by Therapy Area and Indication, 2010
National Taiwan University Hospital – Pipeline by Stage of Development, 2010
National Taiwan University Hospital – Monotherapy Products in Pipeline, 2010
National Taiwan University Hospital – Combination Treatment Modalities in Pipeline, 2010
National Taiwan University Hospital – Pipeline By Therapeutic Class, 2010
National Taiwan University Hospital - Pipeline By Target, 2010
National Taiwan University Hospital – Pipeline By Route of Administration, 2010
National Taiwan University Hospital – Pipeline By Molecule Type, 2010 85